CCND1 and B-cell non-Hodgkin lymphoma: As an initial screen to investigate whether the therapeutic efficacy of anti-CD20 could be enhanced by combination with immunomodulatory mAbs, we used the syngeneic, immunocompetent murine B cell lymphoma model, BCL1 (Slavin and Strober, 1978).